Lupus & antiphospholipid syndrome
Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
Authors' conclusion
Telitacicept demonstrated favourable efficacy and safety in patients with active SLE and improved the renal and haematological manifestations of the disease.
Study context
- Population
- Patients with active SLE treated with telitacicept in everyday clinical practice, multiple centres in China, 2019–202221 treated for 52 weeks
- Participants
- 72 patients
- Outcome
- SRI-4 response
- Follow-up
- 4, 12, 24 and 52 weeks
Methodological detailsmulticentre, real-world, trajectory analysis, multivariable logistic regression
- Multicentre
- Real-world
- Trajectory analysis
- Multivariable logistic regression
Main finding
As reported in the abstract
SRI-4 at 4 weeks
22.22%
SRI-4 at 12 weeks
54.17%
SRI-4 at 24 weeks
72.22%
SRI-4 at 52 weeks
80.95%
Observational data: associations, not effects.
Further findings
LLDAS · 4, 12, 24 and 52 weeks
- LLDAS at 4 weeks
- 8.33%
- LLDAS at 12 weeks
- 26.39%
- LLDAS at 24 weeks
- 34.72%
- LLDAS at 52 weeks
- 47.62%
Remission · 4, 12, 24 and 52 weeks
- Remission at 4 weeks
- 0%
- Remission at 12 weeks
- 4.17%
- Remission at 24 weeks
- 8.33%
- Remission at 52 weeks
- 23.81%
Serum IgA, IgG and IgM · 4, 12, 24 and 52 weeks
- Significant decreases at 4 weeks, downward trend at 12, 24 and 52 weeks
Median 24-hour urinary protein in LN (subgroup) · 52 weeks
mg
- Baseline
- 1323.5
- After 52 weeks
- 224.0
Recovery of haematological abnormalities (subgroup) · 52 weeks
- Recovered
- 10 of 13
Factors for limited response
- Age appeared to have a negative impact on treatment efficacy
Safety
Severe adverse events · observation period
- No severe adverse events reported
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →